The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will support the acceleration of clinical programmes for three of Xeltis’ revolutionary, restorative devices. The [...]

Xeltis announced today that is planning to accelerate its clinical trial program for three restorative devices in parallel. CEO Eliane Schutte provided a sneak preview on Xeltis' plans to an audience of investors and [...]

Leading global research institutions will be presenting results from joint research on Xeltis restorative devices at TERMIS 6th World Congress in Maastricht 15-18 November. Organised by the Tissue Engineering and Regenerative Medicine International Society, [...]

The XABG restorative coronary artery bypass graft (CABG) by Xeltis will feature in a session on the future of vascular therapeutic at the European Symposium on Vascular Biomaterials (ESVB) meeting. In his presentation “Xeltis: [...]

Xeltis’ CTO and Co-Founder Martijn Cox will present insights on the XABG device, the company’s restorative coronary artery bypass graft, at 2021 Vascular Biology meeting organized by the North American Vascular Biology Organization (NAVBO). [...]

Xeltis’ restorative coronary artery bypass graft (CABG), the XABG device, featured at two podium presentations at 2021 European Association for Cardio-Thoracic Surgery (EACTS) annual meeting. In a session about the science behind the future [...]

The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living heart valves or blood vessels, have been published in peer-reviewed journal Acta Biomaterialia. Leading [...]

At Xeltis, we are marking World Heart Day thinking of all people born or leaving with heart disease. They give meaning to our working days and a greater purpose to our jobs. We have [...]